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Abstract 
Renal cell carcinoma is an aggressive disease with a high rate of mortality. It is known to 
metastasize to the lung, liver, bone and brain. However, manifestation through lymphatic 
spread to the lungs is rare. Lymphangitic carcinomatosis is commonly observed in 
malignancies of the breast, lung, pancreas, colon and cervix. It is unusual to observe 
lymphangitic carcinomatosis of the lungs due to renal cell carcinoma. Lymphangitic 
carcinomatosis of the lungs may result in severe respiratory distress and may be the direct 
cause of death. Currently, there are no known modalities of preventing or slowing 
lymphangitic carcinomatosis besides treating the primary tumor. However, early detection 
may change the course of the disease and may prolong survival. This is compounded by the 
difficulty involved in diagnosing lymphangitic carcinomatosis of the lung which frequently 
involves lung biopsy. Immunohistochemical studies are often used in conjunction with 
regular histochemistry in ascertaining the primary tumor and in differentiating it from 
pulmonary metastasis. In this case report, we describe the presentation and clinical course 
of renal cell carcinoma in a patient which manifested as lymphangitis carcinomatosa of the 
lungs. The patient underwent surgical resection of the primary tumor with lymph node 
resection but presented with a fulminant lymphangitic carcinomatosis of the lungs within 
two weeks. Immunohistochemistry of the tissue obtained by the biopsy confirmed the 
diagnosis which was subsequently corroborated during his autopsy. This case illustrates the 
necessity of an urgent follow-up of chemotherapy and immunotherapy in such patients. 
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Introduction 
Renal cell carcinoma originates in the renal cortex and usually presents at an 
advanced stage with a 50% mortality rate after 5 years of diagnosis [1]. It classically 
presents as hematuria, flank pain and abdominal mass [2] but may also manifest with a 
variety of paraneoplastic syndromes including anemia, hypercalcemia, erythrocytosis, 
amyloidosis and thrombocytosis [3]. Common sites of metastasis are lung, bone, liver 
and brain. Notably, more than 90% of metastases in the lung have been detected by 
chest X-ray (CXR) in asymptomatic patients [4].  
Pulmonary embolism involves the establishment of the tumor in the pulmonary 
vasculature, but renal cell carcinoma also frequently invades the lymphatic system. 
Isolated lymph node metastases due to renal cell carcinoma are infrequent but have 
been reported in medical literature [5, 6]. Spread beyond the lymph nodes may occur 
through the lymphatic system, resulting in lymphangitic carcinomatosis. Lymphangitis 
carcinomatosa of the lungs is distinct from pulmonary metastases as the tumor emboli 
do not proliferate or spread locally. They are often seen in collections measuring less 
than 10 microns and frequently trigger the coagulation cascade and obstruct the flow of 
blood in pulmonary capillaries. This may result in severe respiratory distress and often 
becomes the direct cause of death. This case report details the presentation and clinical 
course of a patient with renal cell carcinoma who was found to have lymphangitic 
carcinomatosis which rapidly progressed in a time span of two weeks resulting in his 
demise.  
Case Report 
A 49-year-old man with hypertension presented with left flank pain. He denied night sweats 
and weight loss, and was a lifelong non-smoker. MRI showed a left renal mass with extensive 
retroperitoneal lymph node involvement. He underwent radical nephrectomy with retroperitoneal 
lymph node dissection. Hilar lymph nodes (3/3), para-aortic lymph nodes (8/8) and interaortocaval 
lymph nodes (7/7) tested positive for tumor involvement. The left kidney was found to have a 9.8-cm 
mass at the lower pole and biopsy showed clear cell type renal cell carcinoma with focal sarcomatoid 
and rhabdoid cells. Fig. 1a shows high-grade spindle cells in the sarcomatoid focus and fig. 1b shows 
rhabdoid cells with large eccentric nuclei and abundant cytoplasm. The adrenal gland was also found 
to be infiltrated with tumor.  
He was readmitted two weeks later with right flank pain, dyspnea, fever and cough productive 
of yellowish sputum. Physical examination was significant for tachycardia, tachypnea, bilateral 
crepitations in the chest and bilateral 1+ pedal edema. His arterial blood gas showed respiratory 
alkalosis with an elevated alveolar-arterial (A-a) gradient of 52. His CBC showed leukocytosis at 
19,800 cells/µl with 88% neutrophils, hemoglobin of 9.8 g/dl and a platelet count of 588 k/µl. His 
LFTs were deranged with an albumin of 2.5 g/dl, ALK of 315 and AST/ALT of 166/184. His ESR was 
elevated at 134 and BUN/creatinine rapidly rose from 13/1 to 24/1.9. Notably, his CXR showed 
marked infiltration with nodular opacities in all lung fields bilaterally. Fig. 2a shows his CXR during 
his first admission and fig. 2b shows his CXR at the second admission which reveals marked changes 
compared to his initial CXR.  
He was started on Zosyn and vancomycin and was later switched to aztreonam and clindamycin on 
account of worsening renal function. His respiratory and blood cultures were negative for any growth. 
He continued to be febrile, hypoxemic and tachycardic. CT scan to rule out pulmonary embolism could 
not be performed due to renal failure and Doppler ultrasound of the lower extremities was negative 
for DVT. CT scan without contrast showed nodular opacities with extensive septal thickening as 
depicted in fig. 3. An echocardiogram showed a hyperdynamic left ventricle with EF of 80%. The right 
ventricle size and function were normal. Bronchoscopy with transbronchial biopsy of the right medial  
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lobe was done and biopsy samples revealed non-small cell cancer with clear cell features consistent 
with renal cell carcinoma and lymphangectatic invasion. Immunohistochemistry showed that the 
tissue stained positively for vimentin, CD10 and CD 31 as depicted in fig. 4, confirming the renal 
origin of his tumor. His renal function worsened and he was transferred to the medical ICU where he 
developed septic shock, he was made DNR and passed away shortly thereafter. The autopsy report 
showed florid lymphangectatic invasion with focal necrosis, affecting all lobes of both lungs.  
Discussion 
Lymphangitic spread of metastatic cancer has been observed in many malignancies 
including breast, lung, pancreatic, colonic and cervical cancers [7, 8]. Symptoms of 
tachycardia, tachypnea, hypoxemia and clear lung fields in a patient with malignancy 
should raise the suspicion of lymphangitic carcinomatosis. Infiltration of the tumor 
cells into the superficial lymphatic system can be readily detected as lymphedema in 
some malignancies, especially breast cancer. This may even be the initial manifestation 
of a malignancy [9] or may portend massive tumor burden due to an internal 
malignancy [10]. Histologically, this is evidenced by extensive lymphatic invasion by 
cords of tumor cells. The patient may suffer from intense pain, ulceration and necrosis 
if the superficial lymphatic system is affected as against a painless gradual course 
when the deeper lymphatics are involved. Fever and leukocytosis often accompany 
lymphangitic carcinomatosis making an effective diagnosis difficult. Ventilation 
perfusion scans may be normal or may show a mottled appearance with multiple small, 
peripheral, subsegmental perfusion defects with normal ventilation. This pattern can 
be readily distinguished from the pattern seen with thromboemboli. CT angiography 
may show dilated and beaded peripheral pulmonary arteries. Pulmonary angiography 
is insensitive and may show subtle defects including subsegmental filling defects, 
pruning and tortuosity of the third- to fifth-order vessels, or delayed filling of 
segmental arteries. It may however help in ruling out larger thromboemboli. FDG-PET 
similarly may detect large emboli with avid uptake but may not be sensitive to detect 
smaller collections of tumor cells.  
The gold standard of diagnosis is lung biopsy with demonstration of microscopic 
emboli of tumor cells in the pulmonary vasculature and detection of circulating tumor 
cells in the blood drawn from the pulmonary artery catheter. However, it should be 
noted that lymphangitic carcinomatosis may not necessarily be blood borne. 
Pulmonary lymphatics communicate with the lymphatic system of the neck and direct 
extension of head and neck cancers has been observed to occur through this route [11]. 
Lymphangitic carcinomatosis may also present in an insidious manner being the first 
sign of an occult malignancy. It has also been noted to be asymptomatic with the only 
finding being an abnormal CXR [12]. The presence of vimentin and CD10 noted on 
immunohistochemistry confirmed the diagnosis of clear cell renal cell carcinoma in this 
patient. It is interesting to note that the tissue samples of this patient were positive for 
CD31 which inversely correlates with TNM staging and nuclear grade [13]. The 
sarcomatoid features noted in some samples excised during his initial surgery may 
explain the aggressive course of his disease as it has been shown that sarcomatoid 
renal cell carcinoma is a rapidly progressive disease with poor overall survival [14, 15].  
This case report demonstrates the rapid clinical deterioration a patient may 
experience due to pulmonary lymphangitic carcinomatosis. It is notable that this  
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patient underwent successful resection but developed lymphangitic carcinomatosis 
within two weeks which likely was the direct cause of his death. Pulmonary 
lymphangitic carcinomatosis has a poor prognosis especially since it denotes systemic 
metastasis. Early detection with the help of imaging mediated by tumor-specific 
antibodies can result in therapeutic interventions which may slow the progression of 
the disease or may even be life-saving. 
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Fig. 1. Hematoxylin and eosin staining of tumor sample. a High-grade spindle cells in sarcomatoid 
focus. b Rhabdoid cells with large eccentric nuclei and abundant eosinophilic cytoplasm. 
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Fig. 2. CXR depicting the interval change between the first and the second admission. a CXR on 
first admission with no signs of pulmonary involvement. b CXR on second admission depicting 
reticulo-nodular involvement in all lung fields. 
 
 
 
Fig. 3. Axial CT scan depicting extensive involvement of the parenchyma with septal thickening. 
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Fig. 4. Immunohistochemistry of sample obtained from lung biopsy. a Immunostaining for vimentin. 
b Immunostaining for CD10. c Immunostaining for CD31. 
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